Back to Authors

Dall'Igna, Patrizia

0000-0002-3822-3272

Mayo Clinic

Department of Precision and Regenerative Medicine and Jonic Area (DiMePRe-J), Azienda Ospedaliero-Universitaria Consorziale Pediatric Hospital Giovanni XXIII, Bari, Italy.

Citations 1

Contemporary surgical management of pediatric non‐rhabdomyosarcoma soft tissue sarcoma
Polites, Stephanie F. , Rhee, Daniel S. , Dall’Igna, Patrizia , Binitie, Odion , Scharschmidt, Thomas J. , Lautz, Timothy B. , Dasgupta, Roshni , Dall'Igna, Patrizia , Binitie, Odion , Lautz, Timothy , Dasgupta, Roshni , Seitz, Guido

Pediatric Blood & Cancer | August 14, 2024 | Volume: 71 | Issue: 11 | Pages: No page available

10.1002/pbc.31257 Get It

AbstractNon‐rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases. Surgical resection is a cornerstone of therapy, as tumors are often resistant to chemotherapy or radiation. While patients with isolated tumors less than 5 cm may undergo upfront resection, strong consideration should be given to neoadjuvant chemoradiotherapy to ensure negative margins at surgical resection and optimal outcomes. Sentinel lymph node biopsy is strongly recommended for clear cell and epithelioid sarcomas. The most common metastatic site is the lung, and metastases should be resected at the end of therapy, when feasible. Unfortunately, many high‐risk patients progress on therapy, and alternative strategies including earlier metastatic control require investigation.